The total return over the past 12 months is -71.80% vs. +16.94% for the S&P 500. So far it's up -71.54% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (71.80%) | (28.44%) | (48.61%) | (31.88%) | (16.15%) | (24.48%) |
| Total Return CAGR | (71.80%) | (28.44%) | (48.61%) | (31.88%) | (16.15%) | (24.48%) |
| Revenue CAGR | +0.99% | +8.62% | +12.73% | N/A | +38.23% | +22.11% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Heron Therapeutics, Inc. (HRTX)
| Year | Start price | End price | HRTX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.30 | $0.37 | (71.54%) | +14.51% | (86.05%) |
| 2025 | $1.53 | $1.30 | (15.03%) | +17.72% | (32.75%) |
| 2024 | $1.70 | $1.53 | (10.00%) | +24.89% | (34.89%) |
| 2023 | $2.50 | $1.70 | (32.00%) | +26.19% | (58.19%) |
| 2022 | $9.13 | $2.50 | (72.62%) | (18.17%) | (54.45%) |
| 2021 | $21.17 | $9.13 | (56.86%) | +28.74% | (85.60%) |
| 2020 | $23.50 | $21.17 | (9.94%) | +18.37% | (28.31%) |
| 2019 | $25.94 | $23.50 | (9.41%) | +31.22% | (40.63%) |
| 2018 | $18.10 | $25.94 | +43.31% | (4.56%) | +47.87% |
| 2017 | $13.10 | $18.10 | +38.17% | +21.70% | +16.47% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
